Ferrarazzo Giulia, Chiola Silvia, Capitanio Selene, Donegani Maria Isabella, Miceli Alberto, Raffa Stefano, Tagliafico Alberto Stefano, Morbelli Silvia, Bauckneht Matteo
IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
Nuclear Medicine Unit, Department of Health Sciences, University of Genoa, 16132 Genoa, Italy.
Diagnostics (Basel). 2021 Feb 3;11(2):230. doi: 10.3390/diagnostics11020230.
2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron emission tomography/computed tomography (FDG PET/CT) has an established clinical value in the diagnosis and initial staging of multiple myeloma (MM). In the last ten years, a vast body of literature has shown that this tool can also be of high relevance for monitoring therapy responses, making it the recommended imaging approach in this field. Starting from the strengths and weaknesses of radiological imaging in MM, the present review aims to analyze FDG PET/CT's current clinical value focusing on therapy response assessment and objective interpretation criteria for therapy monitoring. Given the potential occurrence of patients with MM showing non-FDG-avid bone disease, new opportunities can be provided by non-FDG PET tracers. Accordingly, the potential role of non-FDG PET tracers in this setting has also been discussed.
2-脱氧-2-[18F]氟-D-葡萄糖（FDG）正电子发射断层扫描/计算机断层扫描（FDG PET/CT）在多发性骨髓瘤（MM）的诊断和初始分期中具有既定的临床价值。在过去十年中，大量文献表明，该工具在监测治疗反应方面也具有高度相关性，使其成为该领域推荐的成像方法。从MM放射成像的优缺点出发，本综述旨在分析FDG PET/CT目前在治疗反应评估和治疗监测客观解释标准方面的临床价值。鉴于MM患者可能出现非FDG摄取性骨病，非FDG PET示踪剂可提供新的机会。因此，也讨论了非FDG PET示踪剂在这种情况下的潜在作用。
